# US 7,632,872 B2 · Analgesic agent for newborn or fetal subjects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,632,872 B2
- Document ID: US7632872B2
- Status: Granted
- Kind: B2
- Application number: 10/524,316
- Filed: 2003-08-05
- Published: 2006-10-19
- Granted: 2009-12-15
- Earliest claimed: 2002-08-05
- Assignees: Protexeon Limited
- Inventors: Nicholas Peter Franks; Mervyn Maze
- Web page: https://patentgrep.com/patent/US7632872B2

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In a first aspect, the present invention relates to the use of xenon in the preparation of a medicament for providing analgesia in a newborn subject and/or a fetal subject. In a second aspect, the invention relates to a method of providing analgesia in a newborn subject, the method comprising administering to the subject a therapeutically effective amount of xenon. In a third aspect, the invention relates to a method of providing analgesia in a fetal subject, the method comprising administering to the mother of the fetal subject a therapeutically effective amount of xenon for both the mother and fetal subject.

## Claims

### Claim 1

A method of providing analgesia in a human newborn subject, the method comprising administering a therapeutically effective amount of an analgesic to a human newborn subject experiencing pain or stress sufficient to necessitate administration of the analgesic, wherein the analgesic is xenon.

### Claim 2 (depends on 1)

The method of claim 1 wherein the newborn subject is a mammal in the first four weeks after birth.

### Claim 3 (depends on 1)

The method of claim 1 wherein the xenon is administered in combination with a sedative, an anaesthetic agent or a further analgesic agent.

### Claim 4 (depends on 1)

The method of claim 1 wherein the medicament is in gaseous form.

### Claim 5 (depends on 1)

The method of claim 1 wherein the medicament is in liquid form.

### Claim 6 (depends on 1)

A method accordingly to claim 1 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 7 (depends on 1)

A method according to claim 1 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.

### Claim 8 (depends on 1)

A method according to claim 1 wherein the xenon is administered in the form of a lipid emulsion.

### Claim 9 (depends on 1)

A method according to claim 1 wherein the xenon is administered intraveneously, neuraxially or transversally.

### Claim 10

A method of providing analgesia in a human fetal subject, the method comprising administering a therapeutically effective amount of an analgesic to a mother of a human fetal subject, the fetal subject experiencing pain or stress sufficient to necessitate administration of the analgesic, wherein the analgesic is xenon.

### Claim 11 (depends on 1)

A method accordingly to claim 1 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 12 (depends on 10)

A method according to claim 10 wherein the xenon is administered in the form of a 20 to 70% o v/v xenon/air mixture.

### Claim 13 (depends on 10)

A method according to claim 10 wherein the xenon is administered in the form of a lipid emulsion.

### Claim 14 (depends on 10)

A method according to claim 10 wherein the xenon is administered intraveneously, neuraxially or transdermally.

### Claim 15 (depends on 10)

The method according to claim 10, wherein the xenon is administered to the mother prior to labor.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the xenon is administered to the mother during labor.

### Claim 17 (depends on 3)

The method of claim 3, wherein the further analgesic agent is an alpha-2-adrenergic agonist, an opiate, or a non-steroidal anti-inflammatory drug.

### Claim 18 (depends on 3)

The method of claim 3, wherein the sedative or anaesthetic agent promotes GABAergic activity.
